Results 161 to 170 of about 76,618 (225)

Mapping the TNFR2-targeting antibody patent landscape: Insights from macro trends to structural signatures. [PDF]

Hum Vaccin Immunother
Chen S, Chen Y, Zhang Y, Yao G, Cai H, Chen X, Hu Y.   +6 more
europepmc   +1 more source

Use of biologic drugs in juvenile idiopathic arthritis patients followed in an adult rheumatology clinic: real-life data from the HUR-BIO biologic registry. [PDF]

Clin Rheumatol
Ata EB, Kılıç L, Fırlatan Yazgan B, Kart Bayram SG, Ekici M, Ünaldı E, Kuştaş AA, Bulat B, Karadağ Ö, Akdoğan A, Apraş Bilgen Ş, Kiraz S, Ertenli İ, Bilginer Y, Özen S, Kalyoncu U.   +15 more
europepmc   +1 more source

Unexpected Role of TNFα Signaling in the Resolution of Postoperative Pain in Mice. [PDF]

J Pain Res
Laumet S, Edwards AM, Inyang KE, Laumet G.   +3 more
europepmc   +1 more source

The diagnostic and therapeutic challenges of pyoderma gangrenosum in a 32-year-old woman with systemic lupus erythematosus: a case report. [PDF]

Ann Med Surg (Lond)
Rahman AA, Datta A, Sabil SS, Barshan AD, Hasan MJ.   +4 more
europepmc   +1 more source

Hepatobiliary disorders associated with TNF-α inhibitors: a pharmacovigilance analysis of FAERS and JADER. [PDF]

Front Immunol
Chen H, Jiang S, Wang J, Zhang A, Zhu L.
europepmc   +1 more source

Rare case report: a man with rheumatoid arthritis developed membranous nephropathy and ANCA-associated vasculitis successively. [PDF]

BMC Nephrol
Bao D, Cui Z, Yao Y, Lu M, Zheng D, Wang Y.   +5 more
europepmc   +1 more source

The epidemiology and biologics treatment patterns of juvenile idiopathic arthritis in Taiwan- an 8-year follow-up. [PDF]

Front Immunol
Hu YC, Huang YL, Yiao SY, Lin MT, Lin FJ, Yang YH.   +5 more
europepmc   +1 more source

Comparative risk of tuberculosis infection with different TNF-α inhibitors in immune-mediated inflammatory diseases: a systematic review and network meta-analysis. [PDF]

Front Immunol
Lv X, Liu Y, Li Y, Zhang Q, Chen S, Liu X, Shi G, Li Y.   +7 more
europepmc   +1 more source

​Did a Non-Medical Biosimilar Switching Policy Cause an Increase in Non-Biologic/Biosimilar Health Care Resource Utilization or Cost in Patients With Inflammatory Arthritis? [PDF]

Arthritis Care Res (Hoboken)
Dang H, Blitz S, Bansback N, Law M, Harrison M.   +4 more
europepmc   +1 more source

Adoption of new treatment options in non-systemic juvenile idiopathic arthritis (JIA) in clinical practice. [PDF]

Pediatr Rheumatol Online J
Lamers HC, Van Nieuwenhove E, Vastert SJ, Jansen MHA, van Royen-Kerkhof A, Swart JF, de Roock S.   +6 more
europepmc   +1 more source